Payment overview · 2025
General Payments
$1,505.69
71 reported records · 28 companies
Healthcare provider profile · identity verified
Ammar Khalifa, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OVERLAND PARK, KS · NPI 1780677948
Verified facts
What the public records show
CMS Open Payments records show Ammar Khalifa, MD received $1,505.69 in general payments during 2025 across 71 reported records.
SHIELD THERAPEUTICS INC accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Gemtesa, Jardiance, Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1247 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $207.53 | 13.8% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $140.01 | 9.3% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $129.27 | 8.6% | 6 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $125.16 | 8.3% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $110.37 | 7.3% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.21 | 6.5% | 5 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $68.69 | 4.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.48 | 4.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.97 | 3.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.95 | 3.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.34 | 2.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.77 | 2.7% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $39.66 | 2.6% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $35.85 | 2.4% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $32.80 | 2.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $28.63 | 1.9% | 2 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $27.64 | 1.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.53 | 1.7% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $22.54 | 1.5% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $22.35 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.36 | 1.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.80 | 1.4% | 1 | 2025 |
| NxStage Medical, Inc. | Unresolved — no canonical attribution shown | $19.99 | 1.3% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $19.45 | 1.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.49 | 1.2% | 1 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.24 | 1.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.84 | 1.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $14.77 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,505.69 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $207.53 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $167.43 | 8 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $125.16 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $101.85 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $101.85 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $97.21 | 5 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $68.69 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.97 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.95 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $41.85 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $39.66 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $35.85 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $35.30 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $33.22 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $32.80 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $28.63 | 2 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $27.64 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| NXSTAGE SYSTEM ONE Normalized: nxstage system one |
Device | NxStage Medical, Inc. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1247 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 243 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
243 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
243 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 24 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1247 | 127 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 1247 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1183 | 172 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1067 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 833 | 143 |
| Furosemide | Furosemide | 804 | 135 |
| Gabapentin | Gabapentin | 694 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 655 | 126 |
| Tamsulosin Hcl | Tamsulosin Hcl | 642 | 109 |
| Potassium Chloride | Potassium Chloride | 640 | 111 |
| Losartan Potassium | Losartan Potassium | 564 | 94 |
| Donepezil Hcl | Donepezil Hcl | 527 | 79 |
| Lisinopril | Lisinopril | 527 | 95 |
| Escitalopram Oxalate | Escitalopram Oxalate | 500 | 81 |
| Trazodone Hcl | Trazodone Hcl | 479 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 471 | 99 |
| Metformin Hcl | Metformin Hcl | 382 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 366 | 52 |
| Mirtazapine | Mirtazapine | 321 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 308 | 54 |
| Memantine Hcl | Memantine Hcl | 308 | 52 |
| Carvedilol | Carvedilol | 305 | 66 |
| Famotidine | Famotidine | 302 | 63 |
| Levetiracetam | Levetiracetam | 269 | 40 |
| Sertraline Hcl | Sertraline Hcl | 263 | 44 |
| Jardiance | Empagliflozin | 243 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 235 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 44 |
| Myrbetriq | Mirabegron | 215 | 20 |
| Omeprazole | Omeprazole | 214 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 208 | 35 |
| Tramadol Hcl | Tramadol Hcl | 205 | 63 |
| Finasteride | Finasteride | 196 | 33 |
| Xarelto | Rivaroxaban | 196 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 45 |
| Simvastatin | Simvastatin | 172 | 28 |
| Buspirone Hcl | Buspirone Hcl | 159 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 156 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 156 | 46 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 151 | 22 |
| Allopurinol | Allopurinol | 146 | 27 |
| Januvia | Sitagliptin Phosphate | 145 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 141 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 21 |
| Bupropion Xl | Bupropion Hcl | 132 | 24 |
| Warfarin Sodium | Warfarin Sodium | 129 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 128 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 127 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 127 | 25 |
| Latanoprost | Latanoprost | 123 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 49 |
| Prednisone | Prednisone | 122 | 38 |
| Celecoxib | Celecoxib | 117 | 41 |
| Alendronate Sodium | Alendronate Sodium | 115 | 23 |
| Montelukast Sodium | Montelukast Sodium | 115 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 112 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 106 | 55 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 30 |
| Nystatin | Nystatin | 105 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 49 |
| Baclofen | Baclofen | 97 | 19 |
| Meloxicam | Meloxicam | 97 | 21 |
| Ezetimibe | Ezetimibe | 95 | 21 |
| Ozempic | Semaglutide | 94 | 24 |
| Ondansetron Odt | Ondansetron | 92 | 50 |
| Divalproex Sodium | Divalproex Sodium | 90 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 90 | 14 |
| Colestipol Hcl | Colestipol Hcl | 79 | 14 |
| Midodrine Hcl | Midodrine Hcl | 79 | 19 |
| Cephalexin | Cephalexin | 78 | 45 |
| Lamotrigine | Lamotrigine | 77 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 76 | 60 |
| Ondansetron Hcl | Ondansetron Hcl | 76 | 47 |
| Torsemide | Torsemide | 76 | 21 |
| Lorazepam | Lorazepam | 74 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 74 | 16 |
| Primidone | Primidone | 73 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 37 |
| Glimepiride | Glimepiride | 71 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 24 |
| Olanzapine | Olanzapine | 67 | 14 |
| Metformin Hcl Er | Metformin Hcl | 66 | 12 |
| Spironolactone | Spironolactone | 66 | 23 |
| Bumetanide | Bumetanide | 64 | 12 |
| Flecainide Acetate | Flecainide Acetate | 64 | suppressed |
| Amoxicillin | Amoxicillin | 63 | 41 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 37 |
| Santyl | Collagenase Clostridium Hist. | 55 | 14 |
| Alprazolam | Alprazolam | 54 | 19 |
| Risperidone | Risperidone | 52 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 50 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 49 | suppressed |
| Glipizide | Glipizide | 48 | suppressed |
| Timolol Maleate | Timolol Maleate | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 30 |
| Venlafaxine Hcl | Venlafaxine Hcl | 48 | suppressed |
| Digoxin | Digoxin | 47 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 45 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | 13 |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Pregabalin | Pregabalin | 36 | 13 |
| Aripiprazole | Aripiprazole | 35 | 12 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Lactulose | Lactulose | 35 | suppressed |
| Mupirocin | Mupirocin | 35 | 20 |
| Sotalol | Sotalol Hcl | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 16 |
| Valacyclovir | Valacyclovir Hcl | 34 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 33 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Lumigan | Bimatoprost | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | 13 |
| Silver Sulfadiazine | Silver Sulfadiazine | 32 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | 12 |
| Ketoconazole | Ketoconazole | 31 | 16 |
| Prazosin Hcl | Prazosin Hcl | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 31 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 30 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Amantadine | Amantadine Hcl | 29 | suppressed |
| Azithromycin | Azithromycin | 29 | 25 |
| Brimonidine Tartrate | Brimonidine Tartrate | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 15 |
| Loperamide | Loperamide Hcl | 29 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Premarin | Estrogens, Conjugated | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Travoprost | Travoprost | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 22 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 22 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 21 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Enulose | Lactulose | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 11 |
| Methimazole | Methimazole | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Entacapone | Entacapone | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Leflunomide | Leflunomide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 16 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Dofetilide | Dofetilide | 15 | suppressed |
| Hydroxyurea | Hydroxyurea | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Loxapine | Loxapine Succinate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,505.69 · 71 records | SHIELD THERAPEUTICS INC | ACCRUFER, ACTHAR, AFREZZA, CRENESSITY, ELIQUIS, ENTRESTO, EVENITY, FREESTYLE LIBRE 3, Fabhalta, Flector, GEMTESA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, KEVEYIS, Kerendia, Korlym, LEQVIO, Licart, MINIMED 780G, MOUNJARO, NURTEC ODT, NXSTAGE SYSTEM ONE, Ozempic, QULIPTA, RECORLEV, REXULTI, Senza, TARPEYO, TAVNEOS, Tirosint, UBRELVY, UNITHROID, VELPHORO, Vanrafia, XYOSTED, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error